Anaesthesia of choice in renal disease – a) Atracuriumb) Cisatracuriumc) Vecuroniumd) Rocuroniume) Mivacuronium
**Core Concept**
The question tests the understanding of pharmacology in patients with renal disease, focusing on the metabolism and excretion of neuromuscular blocking agents. **Renal impairment** affects the clearance of certain drugs, making some neuromuscular blockers more suitable than others.
**Why the Correct Answer is Right**
Atracurium is the correct answer because it undergoes **Hofmann elimination**, a spontaneous, non-enzymatic degradation process that is independent of renal function. This unique property makes Atracurium an ideal choice for patients with renal disease, as its elimination is not significantly affected by impaired renal function.
**Why Each Wrong Option is Incorrect**
**Option B:** Cisatracurium, although similar to Atracurium in structure and also undergoing Hofmann elimination, is not the primary choice listed here.
**Option C:** Vecuronium is primarily metabolized by the liver and excreted in the bile, but it can accumulate in patients with renal failure due to active metabolites.
**Option D:** Rocuronium is primarily excreted by the liver, but its duration can be prolonged in renal failure due to accumulation of its metabolite.
**Option E:** Mivacurium is metabolized by plasma cholinesterase, and its duration can be unpredictable.
**Clinical Pearl / High-Yield Fact**
In patients with renal disease, choosing an anaesthetic agent that does not rely heavily on renal excretion for its elimination is crucial to avoid prolonged action or toxicity.
**Correct Answer:** B. Cisatracurium